LA
BMRN icon

Lee Ainslie’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lee Ainslie’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,833
Closed -$451K – 357
2021
Q3 		$451K Sell
5,833
-647
-10% -$51K ﹤0.01% 449
2021
Q2 		$541K Buy
+6,480
New +$514K 0.01% 377

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Lee Ainslie's BMRN Position: Q4 2021 in Review

Lee Ainslie sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 5,833 shares — an estimated $451K sold.

Lee Ainslie first reported a position in BMRN in Q2 2021 and held it in 2 quarters. The position peaked at $541K in Q2 2021. 557 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Lee Ainslie reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Lee Ainslie sold 5,833 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $451K.
  • Lee Ainslie first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Lee Ainslie's BioMarin Pharmaceuticals position peaked at $541K in Q2 2021.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.